Drug Research
Zydus Cadila launches a fast tracked programme to develop vaccine for the novel coronavirus, 2019-nCoV (COVID-19)
Zydus Cadila, an innovation-driven, global pharmaceutical company, announced that it has initiated an accelerated research programme with multiple teams in India and Europedeveloping a vaccine for the novel coronavirus, 2019-nCoV (COVID-19) based on two approaches.
The first approach deals with...
Drug Research
Native Antigen Company unveils novel coronavirus antigens
UK-based The Native Antigen Company has commercially introduced novel coronavirus antigens to help fight the ongoing epidemic. The recombinant antigens were obtained from the strain, emerged in Wuhan, China, by using the company’s mammalian, VirtuE expression system.
These antigens help...
Drug Research
K T Rama Rao Inaugurates BE’s Plant at Genome Valley & Unveils Typhoid Conjugate Vaccine
Mr. K T Rama Rao, Honourable Minister for Information Technology, Industries & Commerce, Municipal Administration and Urban Development, Government of Telangana, inaugurated Biological E. Limited’s (BE) Plant and unveiled its new Typhoid Conjugate Vaccine (TCV) today in the Special...
Drug Research
Benzodiazepine Drugs Market Set to Record US$ 2.6 Bn by 2026; the U.S. to Remain Attractive Market
The U.S. is expected to account for around one-third of the total share in the global benzodiazepine drugs market by 2026. Growing prevalence of anxiety in parallel with rising awareness regarding benzodiazepine drugs is reflecting on increasing opportunities for...
Drug Research
Regeneron Announces Expanded Collaboration with HHS to Develop Antibody Treatments for New Coronavirus
Regeneron announced an expanded agreement with the U.S. Department of Health and Human Services (HHS) to develop new treatments combating the novel coronavirus, 2019-nCoV, which was recently declared a global public health emergency by the World Health Organization.
Regeneron has...
Drug Research
Aimmune secures $200m funding from Nestle Health Science
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that Nestlé Health Science will make an additional equity investment in Aimmune of $200 million, bringing Nestlé’s total investment in...
Drug Research
Grey Wolf completes £2.5m Series A2 financing for development of therapies targeting ERAP2
Grey Wolf Therapeutics, a drug discovery biotechnology company focused on developing first-in-class therapies for immuno-oncology (IO), announces it has completed a £2.5 million ($3.3 million) Series A2 financing round with existing leading international healthcare investors Andera Partners and Canaan.
The...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read